Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I

Executive Summary

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.

You may also be interested in...



Frontrunner Kymera Claims Proof-Of-Concept For Protein Degrader Platform

Kymera has unveiled the first placebo-controlled data from a protein degradation candidate, adding to heightened expectations for the novel modality.

Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader

Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.

New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction

In 2020, investors poured millions of dollars into biotech companies searching for new therapeutics that interact with cellular processes involving the destruction and recycling of cellular proteins. These protein degradation-targeted therapies, and molecular glues, have been attracting the attention of big pharma too.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142553

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel